Bixiye
P48-22 Reimbursement Policy Update for -CO and -CQ Modifiers for Minnesota Health Care Programs
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Natiijooyinka Raadinta
Soo bandhiga 931 - 940 ee natiijooyinka 4161
Bixiye
P49-22 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Bixiye
2022 August Bulletins
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Bixiye
QP61-22 Free Continuing Education for Mental Health Providers through 12/31/22
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP62-22 Commercial Pharmacy Benefit Exclusion for Propel®, Propel Mini®, Sinuva®
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP63-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Ryplazim® (plasminogen, human-tvmh)
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP55-22 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2022
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP56-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Cibinqo™ (abrocitinib)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP57-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Pyrukynd® (mitapivat)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP58-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Recorlev® (levoketoconazole)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022